Related Experiment Video
Updated: Mar 31, 2026
11:20
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
4.5K
Sirolimus for Retinal and Uveitic Diseases
Developments in Ophthalmology
|October 27, 2015
Summary
Sirolimus effectively inhibits T-cell proliferation, offering a promising steroid-sparing treatment for chronic inflammatory eye diseases like diabetic retinopathy and uveitis. Clinical trials show encouraging safety and efficacy, positioning it as a valuable therapeutic option.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Chronic inflammation is a key factor in ocular diseases such as diabetic retinopathy, uveitis, and age-related macular degeneration.
- T-cell activation and proliferation contribute to pathological changes causing significant visual morbidity.
Purpose of the Study:
- To review the mechanisms of action, preclinical findings, and clinical trial data for sirolimus in treating human eye diseases.
- To highlight the potential of sirolimus as a steroid-sparing agent in ocular inflammatory conditions.
Main Methods:
- Review of preclinical studies in experimental models of ocular diseases.
- Analysis of early phase I/II human clinical trial data for safety and efficacy.
- Inclusion of key highlights from ongoing phase III clinical trials.
Main Results:
- Preclinical studies demonstrated promising results for sirolimus in various ocular conditions.
- Early phase human trials provided encouraging safety and efficacy data.
- Sirolimus demonstrates potential as a steroid-sparing therapeutic agent targeting inflammatory pathways.
Conclusions:
- Sirolimus inhibits T-cell proliferation, a crucial mechanism in managing inflammatory eye diseases.
- Clinical evidence supports the safety and efficacy of sirolimus for ocular conditions.
- Sirolimus represents a significant addition to the therapeutic options for steroid-sparing treatment of inflammatory eye diseases.
